ChemoMetec A/S (CHEMM) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of ChemoMetec A/S DKK 471, price DKK 517, upside -8.8%, quality 80 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch ChemoMetec A/S for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range kr 236.80 – kr 1,079 · fair‑value band kr 306.44 – kr 671.94 · the kr 516.50 price screens above the kr 471.30 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow ChemoMetec A/S in your weekly email
Every Wednesday you see whether ChemoMetec A/S is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally.
Show more
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter SP-100, an automated sperm cell counter for use in animal reproduction; and XcytoMatic 40, a cell density and viability analyzer. In addition, the company provides consumables comprising cassettes, reagents, lysis, and slides; accessories, which include cables, power supplies, software, and labware products, as well as service and validation plans and training. Further, it develops XcytoMatic 30 cell counter and Xcyto 5, a versatile cell analyzer. ChemoMetec A/S was incorporated in 1997 and is headquartered in Allerød, Denmark.
Stock analysis
ChemoMetec A/S (CHEMM) currently trades at kr 516.50, while our model-based Fair Value estimate is kr 471.30, implying the stock looks roughly 9.6% fairly valued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of kr 311.56 per share, and 0 of the 26 models we run sit above the kr 516.50 price.
Bear case: the Dividend Discount group reads lowest at kr 51.15, and 26 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: kr 306.44 (bear) to kr 671.94 (bull), the price of kr 516.50 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 80/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
ChemoMetec A/S reported revenue of 496M DKK in FY2025 versus 281M DKK in FY2021, a compound +15.2%/yr. Reported net income was 186M DKK in FY2025, compounding +20.5%/yr from FY2021.
Key figures
Market cap 9.0B DKK (≈ $1.4B) · P/E ratio 50.8 · P/S ratio 19.1 · EPS (TTM) kr 10.16 · Dividend yield 1.4% · Net margin 37.6% · Return on equity 28.3% · Return on assets (EBIT) 33.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 35% below its 52-week high and 118% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −9%, CHEMM screens richer than that median.
Fair Value models
Bear kr 306.44Fair Value kr 471.30Bull kr 671.94
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (kr 3.16 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+21.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.3%
Start year 2020 (pandemic). Over 10 years: +23.3% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+26.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+25.0%
Dividend (yield on the price)1.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.25% vs 36%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.36% → 50%
Start year 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+32.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+6.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (Denmark: IMF forecast 2.1% a year to 2030, 2.0% from 2016 to 2025) that is about +30.2% a year for the price and +4.1% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (65 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Very negative
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 361 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score80 · Top 25%
Fair Value upside0% · Above median
Profitability
Return on equity (TTM)28% · Top 25%
Return on assets19% · Top 25%
Net margin (TTM)36% · Top 25%
Operating margin (TTM)48% · Top 25%
Growth and dividend
Revenue growth−1% · Below median
Dividend yield (TTM)1.4% · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "ChemoMetec A/S Fair Value". https://www.fairvalue-calculator.com/stock/CHEMM
Frequently asked questions
Is ChemoMetec A/S (CHEMM) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of kr 471.30 versus a price of kr 516.50, about −9% upside (fairly valued).
What is the fair value of CHEMM?
Our model-based fair value for ChemoMetec A/S is kr 471.30 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 516.50.
What is the quality score of CHEMM?
ChemoMetec A/S has a Quality Score of 80/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ChemoMetec A/S (CHEMM)?
Our model-based price target is the fair value of kr 471.30 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario kr 306.44, optimistic scenario kr 671.94. It is a calculation from audited fundamentals, not an analyst target.
What is the ChemoMetec A/S stock forecast for 2026?
Our models put fair value at kr 471.30, about −9% upside versus a price of kr 516.50 (fairly valued). Cautious scenario kr 306.44, optimistic scenario kr 671.94. The calculation is refreshed regularly with new filings.
What is the revenue of ChemoMetec A/S (CHEMM)?
ChemoMetec A/S reported trailing-twelve-month revenue of about 493M DKK (latest available figure, as of Sep 24, 2026).
Does ChemoMetec A/S pay a dividend?
ChemoMetec A/S currently shows a dividend yield of about 1.36% relative to its recent price (as of Sep 24, 2026).
What growth is priced into ChemoMetec A/S (CHEMM)?
For today's price to be fair in a discounted-cash-flow model, ChemoMetec A/S would have to grow free cash flow by +32.9 % per year for five years (discount rate 12.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +18.3 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of CHEMM use?
Our models discount ChemoMetec A/S at 12.0 %: a base by market capitalisation (small), damped by beta 1.36, country premium for Denmark. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For ChemoMetec A/S that is +32.9 % per year a year over ten years, using the same discount rate (12.0 %) and the same formula as our fair value.
How much growth has ChemoMetec A/S (CHEMM) delivered so far?
Over the past 5 years revenue at ChemoMetec A/S grew +18.3 % a year. The price currently implies +32.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of ChemoMetec A/S (CHEMM) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into ChemoMetec A/S (+32.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of ChemoMetec A/S (CHEMM)?
The free-cash-flow yield on the price is 1.98 %: that much free cash flow ChemoMetec A/S produces per unit of market value. When it exceeds the discount rate of our models (12.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of ChemoMetec A/S (CHEMM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ChemoMetec A/S it is kr 471.30 per share (as of Sep 24, 2026), against a price of kr 516.50. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is ChemoMetec A/S stock overvalued or undervalued in 2026?
As of Sep 24, 2026, CHEMM trades above its calculated fair value: price kr 516.50, fair value kr 471.30, a gap of about −9% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CHEMM?
No. The price is what the market pays today (kr 516.50); the fair value is what the company's own numbers justify (kr 471.30). For ChemoMetec A/S the two are kr 45.20 per share apart. That gap is exactly why we show both numbers side by side.
How much is ChemoMetec A/S worth?
The market values ChemoMetec A/S at about 9.0B DKK (market capitalisation, as of Sep 24, 2026). Per share that is kr 516.50; our models calculate a fair value of kr 471.30 per share.
What do the bullish and bearish scenarios say about CHEMM?
Our models span a range for ChemoMetec A/S: cautious scenario kr 306.44, base kr 471.30, optimistic kr 671.94 per share (as of Sep 24, 2026, price kr 516.50). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CHEMM?
ChemoMetec A/S trades at a price-to-earnings ratio of 50.8 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 471.30 is built from several models across several years. Other multiples: P/B 13.4, P/S 18.2, EV/EBITDA 35.4.
How solid is the balance sheet of ChemoMetec A/S (CHEMM)?
Balance-sheet figures for ChemoMetec A/S (as of Sep 24, 2026): return on equity 28.3%. They feed the Quality Score of 80/100, which measures business quality independently of the share price.
How far is CHEMM from its 52-week high?
ChemoMetec A/S trades at kr 516.50, about 35% below its 52-week high of kr 792.00 and 118% above the low of kr 236.80 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of kr 471.30 is for.
Which stocks are comparable to ChemoMetec A/S?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ChemoMetec A/S stock attractive at the current price?
The data as of Sep 24, 2026: price kr 516.50, calculated fair value kr 471.30 (−9%), Quality Score 80/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CHEMM calculated?
We run ChemoMetec A/S through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 471.30, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. ChemoMetec A/S itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ChemoMetec A/S (CHEMM)?
The closing price on Sep 23, 2026 was kr 516.50. Our model-based fair value is kr 471.30, about −9% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ChemoMetec A/S right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (kr 306.44 to kr 671.94) leaves room in how you read the outcome.
Where does the earnings growth of ChemoMetec A/S (CHEMM) come from?
Earnings per share at ChemoMetec A/S grew +42.3 % a year from 2014 to 2025. Broken into its drivers: revenue per share +23.2 %, EBIT margin +16.8 %, tax rate −1.7 %, residual (interest, one-offs) +0.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of ChemoMetec A/S
How large is the market capitalisation of ChemoMetec A/S (CHEMM)?
The market capitalisation of ChemoMetec A/S is 9.0B DKK (≈ $1.4B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ChemoMetec A/S (CHEMM)?
The price-to-sales ratio of ChemoMetec A/S is 19.1 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of ChemoMetec A/S (CHEMM)?
Earnings per share at ChemoMetec A/S are kr 10.16 (price ÷ EPS = P/E 50.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of ChemoMetec A/S (CHEMM)?
The dividend yield of ChemoMetec A/S is 1.4% (payout 68.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of ChemoMetec A/S (CHEMM)?
The net margin of ChemoMetec A/S is 37.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ChemoMetec A/S (CHEMM)?
The return on equity (ROE) of ChemoMetec A/S is 28.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ChemoMetec A/S (CHEMM)?
On an EBIT basis the return on assets of ChemoMetec A/S is 33.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ChemoMetec A/S (CHEMM)?
The operating margin of ChemoMetec A/S is 48.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ChemoMetec A/S (CHEMM)?
Revenue at ChemoMetec A/S is growing −1.0% versus a year earlier (3y avg +5.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ChemoMetec A/S (CHEMM)?
Earnings per share at ChemoMetec A/S are growing −9.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does ChemoMetec A/S (CHEMM) hold?
ChemoMetec A/S holds more cash than debt, 335M DKK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch ChemoMetec A/S in the live analysis
One click puts ChemoMetec A/S on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
